Burrill conference to provide insights into challenges and opportunities in personalized medicine

Thanks to the accelerating pace of scientific discovery in life sciences, coupled with our ability to process and analyze enormous amounts of genetic information, the field of personalized medicine has evolved.

"Healthcare is now shifting towards predictive and preventative care utilizing diagnostics that allow physicians to follow the course of a disease, evaluate which therapeutic regimes are most effective, and determine long-term susceptibility and recurrence," said G. Steven Burrill, CEO of Burrill & Company. "As diseases are better understood at a molecular level, the promise of personalized medicine is becoming a reality.

"In addition, personalized medicine now extends beyond targeted therapeutics and diagnostics to encompass a 'consumer digital health' world that includes areas such as: personal health record management, health IT, wellness and nutrition," added Burrill, "and we will be providing delegates with an update to what this means for personalized medicine."

The 6th Annual Burrill Personalized Medicine conference, to be held in San Francisco, September 27-28, 2010, will update attendees on where we are today in the context of a turbulent, challenging economy, and a "post healthcare reform environment."  The two-day meeting will bring together stakeholders from across the value chain of personalized medicine for a fascinating set of "conversations" on key topics including: "Has "Healthcare Reform" accelerated or decelerated the move to a more personalized medicine world?" "The Translational Challenge: Building the Scientific Infrastructure for Personalized Medicine" and "What Will it Take to Get Patients to Believe in Personalized Medicine and Can Medicine Deliver on this Promise?"

The 6th Annual Burrill Personalized Medicine conference, presented this year in association with the Duke Institute for Genome Sciences and Policy, has become a "must attend" event providing an annual window into the progress of personalized medicine and the challenges and opportunities that this new paradigm presents.

Further details on the agenda may be obtained from: http://www.burrillandco.com/personalized_medicine_2010/